The physiologically elevated uPAR expression in these organs, which has been previously documented in the literature,[31, 32] may limit the surgical application of uPAR‐targeting Nbs (and by extension also other uPAR‐targeting contrast agents), in particular for lung cancer. The gene discussed is PLAUR; the disease is lung carcinoma.